Current Cardiology Reports, Год журнала: 2024, Номер unknown
Опубликована: Сен. 5, 2024
Язык: Английский
Annals of Internal Medicine, Год журнала: 2024, Номер 177(5), С. ITC65 - ITC80
Опубликована: Май 1, 2024
Obesity is a common condition and major cause of morbidity mortality. Fortunately, weight loss treatment can reduce obesity-related complications. This review summarizes the evidence-based strategies physicians employ to identify, prevent, treat obesity, including best practices diagnose counsel patients, assess address burden weight-related disease stigma, secondary causes gain, help patients set individualized realistic goals an effective plan. Effective treatments include lifestyle modification adjunctive therapies such as antiobesity medications metabolic bariatric surgery.
Язык: Английский
Процитировано
26
Diabetes Technology & Therapeutics, Год журнала: 2024, Номер 26(6), С. 367 - 374
Опубликована: Март 21, 2024
Most patients with type 1 diabetes (T1D) in the United States are overweight (OW) or obese (OB), contributing to insulin resistance and suboptimal glucose control. The primary Food Drug Administration-approved treatment for T1D is insulin, which may adversely affect weight. Tirzepatide approved managing 2 diabetes, improves control, facilitates weight loss, cardiovascular disease outcomes. We assessed use of tirzepatide OW/OB subjects T1D.
Язык: Английский
Процитировано
25
Metabolism, Год журнала: 2024, Номер 159, С. 155931 - 155931
Опубликована: Июнь 7, 2024
Язык: Английский
Процитировано
24
Diabetes Obesity and Metabolism, Год журнала: 2025, Номер unknown
Опубликована: Март 11, 2025
Abstract Obesity is a highly prevalent chronic multisystem disease associated with shortened life expectancy due to number of adverse health outcomes. Epidemiological data link body weight and parameters central fat distribution an increasing risk for type 2 diabetes, hypertension, fatty liver diseases, cardiovascular diseases including myocardial infarction, heart failure, atrial fibrillation, stroke, obstructive sleep apnoea, osteoarthritis, mental disorders some types cancer. However, the individual develop cardiometabolic other obesity‐related cannot entirely be explained by increased mass. Rather than excess accumulation, dysfunction adipose tissue may represent mechanistic between obesity There are people living who seem protected against premature development diseases. On hand, normal typical upon predominantly visceral distribution. The mechanisms linking impaired function in include adipocyte hypertrophy, altered cellular composition, limited expandability safe subcutaneous stores, ectopic deposition depots, organs, hypoxia, variety stresses, inflammatory processes, release pro‐inflammatory, diabetogenic atherogenic signals. Genetic environmental factors might contribute either alone or via interaction intrinsic biological variation function. still many open questions regarding how causes whether these pathologies could reversed. Evidence‐based loss interventions using behaviour change, pharmacological surgical approaches have clarified beneficial effects realistic sustained on complications as hard This review focusses recent advances understanding epidemiological trends Plain Language Summary complex progressive characterized excessive that impair quality life. Worldwide, adults has more doubled since 1990. lead reduced expectancy, because it increases (e.g., high blood pressure, stroke), musculoskeletal respiratory depression certain not every person develops For better prevention treatment, important understand mass related It become clear explain higher complications. People can low developing Compared those abdominal region, average bigger cells, immune cells signals released from directly affect brain, liver, vasculature organs. Both inherited environment cause abnormalities through changes lower calorie intake, physical activity), medications surgery improve health, reduce
Язык: Английский
Процитировано
3
Circulation Research, Год журнала: 2025, Номер 136(6), С. 594 - 605
Опубликована: Март 13, 2025
Obesity in women is a significant public health issue with serious implications for cardiovascular-kidney-metabolic syndrome and cardiovascular disease. This complex challenge influenced by physiological, hormonal, socioeconomic, cultural factors. Women face unique weight management challenges due to hormonal changes during pregnancy, perimenopause, menopause, which affect fat distribution increase risk. Current clinical guidelines often overlook these sex-specific factors, potentially limiting the effectiveness of obesity strategies women. review explores aspects obesity’s pathophysiology, epidemiological trends, associated comorbidities, focusing on metabolic complications. synthesizes literature women, emphasizing factors influencing its development progression. It examines limitations body mass index as an measure alternative classification methods. Additionally it investigates relationship between comorbidities such diabetes, hypertension, dyslipidemia, focus postmenopausal linked increased risks Hormonal fluctuations throughout life contribute gain patterns specific increasing disease Effective must account variations. Postmenopausal are particularly affected obesity-related Lifestyle interventions, pharmacotherapy, bariatric surgery have shown efficacy management, though success rates vary. Addressing requires comprehensive approach that considers physiological life-stage challenges, sociocultural barriers. Integrating precision medicine emerging therapies offers potential more personalized effective interventions. Personalized consider women’s biological can enhance improve outcomes. Future research practice should developing tailored address vulnerabilities validating interventions
Язык: Английский
Процитировано
3
Diabetes Therapy, Год журнала: 2024, Номер 15(9), С. 1865 - 1892
Опубликована: Июль 11, 2024
The increasing global incidence of obesity and type 2 diabetes mellitus (T2D) underscores the urgency addressing these interconnected health challenges. Obesity enhances genetic environmental influences on T2D, being not only a primary risk factor but also exacerbating its severity. complex mechanisms linking T2D involve adiposity-driven changes in β-cell function, adipose tissue functioning, multi-organ insulin resistance (IR). Early detection tailored treatment are crucial to mitigate future complications. Moreover, personalized early intensified therapy considering presence comorbidities can delay disease progression diminish cardiorenal Employing combination therapies embracing disease-modifying strategy paramount. Clinical trials provide evidence confirming efficacy safety glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Their use is associated with substantial durable body weight reduction, exceeding 15%, improved glucose control which further translate into prevention, possible remission, improvement cardiometabolic factors Therefore, basis clinical experience current evidence, Eastern Southern Europe Diabetes Expert Group recommends personalized, polymodal approach (comprising GLP-1 RAs) individual patient's phenotype optimize therapy. We expect that availability dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) will significantly contribute modern management continuum.
Язык: Английский
Процитировано
16
Obesity Pillars, Год журнала: 2024, Номер 11, С. 100121 - 100121
Опубликована: Июль 25, 2024
Obesity and type 2 diabetes mellitus (T2DM) are increasingly common in the United States worldwide. Because both conditions associated with serious health consequences, weight reduction is recommended by professional medical nutrition societies to improve outcomes. Due striking efficacy of glucagon-like peptide receptor agonists (GLP-1RAs) dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like (GIP/GLP-1RAs) for glycemic control, there increased utilization patients obesity and/or T2DM. Yet, impact these medications on dietary intake less understood. This narrative literature review summarizes clinical studies quantifying characterizing people T2DM using GLP-1 or GIP/GLP-1 RAs. Though data from reveal that total caloric was reduced 16–39 %, few evaluated actual composition diet. Further research needed understand unique nutritional needs adults GIP/GLP-1RAs support development guidelines individuals.
Язык: Английский
Процитировано
16
Biomedicines, Год журнала: 2024, Номер 12(6), С. 1320 - 1320
Опубликована: Июнь 13, 2024
Guidelines for the management of obesity and type 2 diabetes (T2DM) emphasize importance lifestyle changes, including a reduced-calorie diet increased physical activity. However, many people, these changes can be difficult to maintain over long term. Medication options are already available treat obesity, which help reduce appetite and/or caloric intake. Incretin-based peptides exert their effect through G-protein-coupled receptors, receptors glucagon-like peptide-1 (GLP-1) glucose-dependent insulinotropic polypeptide (GIP), glucagon peptide hormones important regulators insulin secretion energy metabolism. Understanding role intercellular signaling pathways inflammatory processes is essential development effective pharmacological agents in obesity. GLP-1 receptor agonists have been successfully used, but it assumed that effectiveness may limited by desensitization downregulation target receptor. A growing number new acting on incretin becoming everyday clinical practice, oral agonists, dual GLP-1/GIP agonist tirzepatide, other triple GLP-1/GIP/glucagon show further significant therapeutic potential. This narrative review summarizes effects different presents future prospects treatment T2DM
Язык: Английский
Процитировано
13
Journal of Endocrinological Investigation, Год журнала: 2024, Номер 47(6), С. 1395 - 1403
Опубликована: Фев. 18, 2024
Abstract Aim Oral semaglutide, an innovative orally administered GLP-1 receptor agonist for type 2 diabetes (T2D) management was herein evaluated its effectiveness in a multi-center retrospective real-world study. Methods We included new-users of oral semaglutide from 18 specialist care centres and collected data on baseline clinical characteristics. Updated values HbA1c body weight were analyzed using the mixed model repeated measures. Results The study 166 individuals with T2D, predominantly men (64.5%), mean age 64.4 years duration 10.1 years. In majority patients (68.3%) used as second-line drug, mostly metformin. At baseline, BMI 28.9 kg/m 7.5%. During 18-month observation period, demonstrated significant reductions HbA1c, maximum change − 0.9%, 42.1% achieved below 7.0%. Additionally, there substantial reduction weight, estimated 3.4 kg at months, 30.3% experienced 5% or greater weight. Only 24.2% reached 14 mg dose. Subgroup analysis revealed that > 7%, persistence not being prior therapy DPP-4 inhibitors, loosing more initial associated reductions. Conclusion This supports effective option T2D treatment, offering improved glucose control setting.
Язык: Английский
Процитировано
10
Diabetes Care, Год журнала: 2024, Номер 47(4), С. 544 - 555
Опубликована: Март 25, 2024
This statement provides guidance for diabetes care in detention facilities. It focuses on areas where the processes delivery of to people with facilities may differ from those community, and key points are made at end each section. Areas emphasis, which inform multiple aspects discussed this statement, include 1) timely identification or diagnosis treatment needs continuity (at reception/intake, during transfers, upon discharge), 2) nutrition physical activity, 3) access management tools (insulin, blood glucose monitoring, tracking data, current technologies, etc.), 4) whole person (self-management education, mental health support, monitoring addressing long-term complications, specialty care, etc.).
Язык: Английский
Процитировано
9